News

Article

Trastuzumab Deruxtecan Improves PFS in Metastatic HR+/HER2-Low Breast Cancer After Endocrine Therapy

Author(s):

Trastuzumab deruxtecan improved PFS vs chemotherapy in HR-positive, HER2-low metastatic breast cancer after 1 or more lines of endocrine therapy.

Susan Galbraith

Susan Galbraith

Treatment with fam-trastuzumab deruxtecan-nxki (Enhertu) led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with standard-of-care (SOC) chemotherapy in patients with metastatic hormone receptor (HR)–positive, HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in situ hybridization [ISH]–) breast cancer after 1 or more lines of endocrine therapy, according to topline results from the phase 3 DESTINY-Breast06 trial (NCT04494425).1

Furthermore, a statistically significant and clinically meaningful improvement in PFS was observed in the overall trial population, which included patients with HER2-low and HER2-ultralow disease (IHC 0 with membrane staining; IHC >0 <1+). Although overall survival (OS) data were not mature, a trend favoring trastuzumab deruxtecan was observed in both the overall and HR-positive, HER2-low populations.

No new safety signals were reported, and the safety profile of the antibody-drug conjugate was consistent with findings from previous clinical trials.

Full data from DESTINY-Breast06 will be presented at an upcoming medical meeting and shared with global health authorities.

“DESTINY-Breast06 shows that [trastuzumab deruxtecan] could become a new SOC for patients with HER2-low and HER2-ultralow metastatic breast cancer following 1 or more lines of endocrine therapy,” Susan Galbraith, executive vice president of Oncology R&D at AstraZeneca, stated in a news release. “These data underscore the potential for treatment with [trastuzumab deruxtecan] across the spectrum of HR-positive breast cancer, further redefining the treatment of metastatic breast cancer.”

In August 2022, the FDA approved trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. This approval was based on data from the phase 3 DESTINY-Breast04 trial (NCT03734029).2

DESTINY-Breast06 was a global, randomized, open-label trial that enrolled patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining; IHC >0 <1+) advanced or metastatic breast cancer. No prior chemotherapy for advanced or metastatic disease was permitted. Patients were required to have disease progression within 6 months of the initiation of first-line therapy consisting of endocrine therapy in combination with a CDK4/6 inhibitor, or they need to have at least 2 prior lines of endocrine therapy in the metastatic setting.1

Investigators enrolled 866 patients with HER2-low (n = 713) or HER2-ultralow (n = 153) disease across sites in Asia, Europe, North America, and South America.

Patients were randomly assigned to receive trastuzumab deruxtecan or chemotherapy, which consisted of capecitabine (Xeloda), paclitaxel, or nab-paclitaxel (Abraxane).

PFS per blinded independent central review (BICR) in patients with HR-positive, HER2-low disease served as the trial’s primary end point. Secondary end points included OS in the HER2-low population; PFS per BICR and OS in the overall trial population; objective response rate; duration of response; time to first subsequent treatment or death; time to second subsequent treatment or death; and safety. Notably, analyses of the HER2-ultralow subgroup are not powered to demonstrate statistical significance.

“The topline results from DESTINY-Breast06 highlight the importance of continuing to challenge current treatment paradigms and established breast cancer classifications to evolve how we treat patients with HR-positive, HER2-expressing metastatic breast cancer,” Ken Takeshita, global head of R&D at Daiichi Sankyo, added in a news release. “Building on the practice-changing data seen in DESTINY-Breast04, these results reinforce the potential for use of [trastuzumab deruxtecan] earlier in the treatment landscape and in an even broader patient population.”

References

  1. Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of endocrine therapy in DESTINY-Breast06 phase III trial. News release. AstraZeneca. April 29, 2024. Accessed April 29, 2024. https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-improved-pfs-in-her2-low-and-ultralow.html
  2. FDA approves fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer. FDA. August 5, 2022. Accessed April 29, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-low-breast-cancer
Related Videos
Sheldon M. Feldman, MD
In this episode of OncChats: Empowering Community Cancer Care, Dr. Rai emphasizes the importance of community outreach and support for patients with cancer, highlighting the need for holistic care that addresses both physiological and psychological aspects of treatment while reinforcing the value of strong relationships between primary care physicians and specialists.
In this episode of OncChats: Empowering Community Cancer Care, Dr. Woodworth sheds light on the “Road to Recovery” survivorship program at Henry Mayo, which supports cancer survivors by providing them with fitness, education, and mental health resources, and underscores the importance of mentorship programs for community providers to ensure equitable cancer care.
In this episode of OncChats: Empowering Community Cancer Care, Drs Woodworth and Rai, discuss their collaborative approach to cancer screening, emphasizing the importance of community efforts and individual assessments in integrating genetic testing and screenings into routine practice.
In this episode of OncChats: Empowering Community Cancer Care, experts discuss the significance of community-based cancer care, emphasizing that most cancers are diagnosed locally and highlighting the importance of collaboration between primary care physicians and specialists to provide optimal education and treatment.
Sunil Adige, MD
Margaret E. Gatti-Mays, MD, MPH, FACP
Sunil Adige, MD
Seth Wander, MD, PhD